Literature DB >> 27628962

Prevention of Epilepsy: Issues and Innovations.

Dieter Schmidt1, Matti Sillanpää2.   

Abstract

Epilepsy is a common brain disease and preventing epilepsy is a very relevant public health concern and an urgent unmet need. Although 40 % of all epilepsy cases are thought to have acquired causes, there is a roadblock for successful prevention. Efforts to protect the brain from epileptogenic insults are severely hampered by our lack of biomarkers to identify the few percent at high risk meriting treatment among those exposed. Preventing brain injury has been moderately effective from around birth to middle age; however, the strategy has failed to stop a substantial increase over the last decades in symptomatic epilepsy in those aged 65 and above. The traditional concept of repurposing anti-seizure drugs used for symptomatic seizure relief to prevent the onset of epilepsy has completely failed up to now. More recently, however, hope is on the horizon with a search for biomarkers and discovery of a new class of agents, called anti-epileptogenic drugs, which were specifically developed for prevention of epilepsy.

Entities:  

Keywords:  Anti-epileptogenic drugs; Brain injury; Disease modification; Epilepsy; Epilepsy prevention; Epileptogenesis; Latent periodtraumatic

Mesh:

Substances:

Year:  2016        PMID: 27628962     DOI: 10.1007/s11910-016-0695-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  17 in total

Review 1.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons.

Authors:  Dieter Schmidt
Journal:  Epileptic Disord       Date:  2012-06       Impact factor: 1.819

Review 3.  Advances in the development of biomarkers for epilepsy.

Authors:  Asla Pitkänen; Wolfgang Löscher; Annamaria Vezzani; Albert J Becker; Michele Simonato; Katarzyna Lukasiuk; Olli Gröhn; Jens P Bankstahl; Alon Friedman; Eleonora Aronica; Jan A Gorter; Teresa Ravizza; Sanjay M Sisodiya; Merab Kokaia; Heinz Beck
Journal:  Lancet Neurol       Date:  2016-07       Impact factor: 44.182

Review 4.  Human clinical trails in antiepileptogenesis.

Authors:  Ram Mani; John Pollard; Marc A Dichter
Journal:  Neurosci Lett       Date:  2011-03-23       Impact factor: 3.046

Review 5.  Preventing and treating posttraumatic seizures: the human experience.

Authors:  Nancy R Temkin
Journal:  Epilepsia       Date:  2009-02       Impact factor: 5.864

6.  Prevention as it pertains to epilepsy.

Authors:  F E Dreifuss
Journal:  Arch Neurol       Date:  1995-04

Review 7.  Anti-epileptogenic clinical trial designs in epilepsy: issues and options.

Authors:  Dieter Schmidt; Daniel Friedman; Marc A Dichter
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 8.  The enigma of the latent period in the development of symptomatic acquired epilepsy - Traditional view versus new concepts.

Authors:  Wolfgang Löscher; Lawrence J Hirsch; Dieter Schmidt
Journal:  Epilepsy Behav       Date:  2015-09-25       Impact factor: 2.937

Review 9.  Past and present definitions of epileptogenesis and its biomarkers.

Authors:  Asla Pitkänen; Jerome Engel
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

10.  Efforts in Epilepsy Prevention in the Last 40 Years: Lessons From a Large Nationwide Study.

Authors:  Matti Sillanpää; Mika Gissler; Dieter Schmidt
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

View more
  4 in total

1.  Toll-like Receptor 4 Signaling in Neurons Enhances Calcium-Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Currents and Drives Post-Traumatic Epileptogenesis.

Authors:  Akshata A Korgaonkar; Ying Li; Dipika Sekhar; Deepak Subramanian; Jenieve Guevarra; Bogumila Swietek; Alexandra Pallottie; Sukwinder Singh; Kruthi Kella; Stella Elkabes; Vijayalakshmi Santhakumar
Journal:  Ann Neurol       Date:  2020-02-24       Impact factor: 10.422

2.  Blood-Brain Barrier Leakage during Early Epileptogenesis Is Associated with Rapid Remodeling of the Neurovascular Unit.

Authors:  Marion Bankstahl; Heike Breuer; Ina Leiter; Martin Märkel; Pablo Bascuñana; Dominik Michalski; Frank M Bengel; Wolfgang Löscher; Martin Meier; Jens P Bankstahl; Wolfgang Härtig
Journal:  eNeuro       Date:  2018-05-30

Review 3.  How to Find Candidate Drug-targets for Antiepileptogenic Therapy?

Authors:  Nian Yu; Xing-Jian Lin; Qing Di
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

4.  CK2 Inhibition Prior to Status Epilepticus Persistently Enhances KCa2 Function in CA1 Which Slows Down Disease Progression.

Authors:  Felix Schulze; Steffen Müller; Xiati Guli; Lukas Schumann; Hannes Brehme; Till Riffert; Marco Rohde; Doreen Goerss; Simone Rackow; Anne Einsle; Timo Kirschstein; Rüdiger Köhling
Journal:  Front Cell Neurosci       Date:  2020-02-26       Impact factor: 5.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.